Werfen USA LLC
$53.8K 148 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pierre Fabre Pharmaceuticals, Inc.
Pierre Fabre Pharmaceuticals, Inc. reported $53,619.53 across General Payments, Research, and Ownership to 165 physicians and teaching hospitals across 165 transactions.
- $53.6K Below-median payer
- All-tracks total
- 165 Above-median volume
- Transactions
- 165 Above-median reach
- Recipients
- −$5.0K
- General Payments vs PY2023
Pierre Fabre Pharmaceuticals, Inc. reported $53,619.53 across all CMS Open Payments tracks (General + Research + Ownership) to 165 physicians and teaching hospitals in Program Year 2024 - ranking #1334 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $53,619.53, averaging $324.97 per recipient.
Pierre Fabre Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pierre-fabre-pharmaceuticals-inc Pierre Fabre Pharmaceuticals, Inc.
$53.6K · #1334/1,925 · 0.0% industry · PY2024
- TOT $53.6K
- RANK #1334
- SHARE 0.0%
- TXN 165
- RCP 165
- CAT 3
- GEN $53.6K
- ΔGEN −$5.0K
- TOP1 14.1%
- PY 2024
Volume peers
Nearest volume peer: Werfen USA LLC ($53.8K)
Pierre Fabre Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pierre Fabre Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $5.0K (−8.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PIERRE FABRE PHARMACEUTICALS, INC.PY2023: PIERRE FABRE PHARMACEUTICALS, INC.PY2024: Pierre Fabre Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $58,579.55
- PY2024
- $53,619.53
What the Data Shows for Pierre Fabre Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Pierre Fabre Pharmaceuticals, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
32 transactions worth $44.9K make "Travel and Lodging" the top general-payment category in the 3-category breakdown below, 83.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 3 types of general payments, Pierre Fabre Pharmaceuticals, Inc.'s largest category was "Travel and Lodging" at $44.9K - 83.8% of General Payments.
How Pierre Fabre Pharmaceuticals, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $44.9K | 32 | 83.8% |
| Food and Beverage | $6.7K | 132 | 12.5% |
| Compensation for Services Other Than Consulting | $2.0K | 1 | 3.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,820.94 (53.8%) of $53,619.53 in this company's General Payments records across 85 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pierre Fabre Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Xavier Sanchez Flores
$7,585.81 across 5 reported transactions
- 2
John Browning
$6,389.84 across 7 reported transactions
- 3
Elizabeth Lewis Nieman
$5,615.89 across 5 reported transactions
- 4
Esteban Fernandez Faith
$5,376.70 across 7 reported transactions
- 5
Adelaide Hebert
$3,852.70 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pierre Fabre Pharmaceuticals, Inc.'s spend rank (#1334 of 1,925, bottom 31% by spend) and concentration rank (#1,115 of 1,838, bottom 39% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Septodont Inc. : $289.4K total payments, HHI 813
- BioHorizons Implant Systems Inc. : $1.4M total payments, HHI 813
- PTC Therapeutics, Inc. : $464.2K total payments, HHI 811
- Planmeca USA, Inc. : $214.2K total payments, HHI 810
- Elevation Spine, Inc. : $38.6K total payments, HHI 810
- Terumo Cardiovascular Systems Corporation : $22.7K total payments, HHI 809
- Pierre Fabre Pharmaceuticals, Inc. (this company) : $53.6K total payments, HHI 809
- Marinus Pharmaceuticals, Inc. : $279.2K total payments, HHI 807
- 3B Medical, Inc. : $29.3K total payments, HHI 805
- ModernaTX, Inc. : $2.4M total payments, HHI 803
- Community Blood Center : $72.5K total payments, HHI 797
- Acrotech Biopharma Inc. : $317.9K total payments, HHI 793
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pierre Fabre Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pierre Fabre Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pierre Fabre Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Minerva Surgical, Inc
$53.9K 1,260 recipients
Compare payment profiles
Integer Holdings Corporation
$54.0K 36 recipients
Compare payment profiles
Sioux Surgical Inc
$53.3K 390 recipients
Compare payment profiles
Eisai Co., Ltd.
$54.3K 17 recipients
Compare payment profiles
On Target Laboratories, Inc
$53.0K 114 recipients
Compare payment profiles
Put this to use
Pierre Fabre Pharmaceuticals, Inc. ranks #1334 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Pierre Fabre Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.